EGEneko Ganuza

Eneko Ganuza

*This is an algorithmically generated author record based on publicly available information.

Eneko Ganuza has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Study Protocol and Baseline Cardiometabolic Characterization of the RIO-Study (Response to an Intervention with Omega-3): A Randomized, Double-Blind, Placebo-Controlled Crossover Trial on Lipid and Inflammatory Profiles in Overweight and Obese Adults with Hypertriglyceridemia in Valdivia, Chile

    by Josefina Enríquez, Consuelo Quezada, Jessica Molina, Matías Sáez, Iarela Mitre, Camila Moreira, Feren Sandoval, Rodrigo Maldonado, Montserrat Fitó, Sebastián Zagmutt, et al.

    Background: Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide, with metabolic syndrome and its risk factors contributing substantially to cases in Latin America. In southern Chile, obesity, dyslipidemia, and sedentary behavior are highly prevalent, yet comprehensive baseline data on these factors are scarce. Establishing regional cardiometabolic profiles is crucial to inform prevention strategies. Objective: To describe the RIO-Study protocol and characterize the baseline cardiometabolic profile of adults from Valdivia, southern Chile. Methods: The RIO-Study is a randomized, double-blind, placebo-controlled, crossover clinical trial evaluating the effects of nutritional doses of seaweed-derived omega-3 fatty acids on lipid metabolism, inflammation, and molecular lipid regulators in adults with overweight/obesity. The protocol includes a standardized high-fat breakfast challenge and repeated postprandial blood sampling to assess dynamic lipid responses. Screening procedures comprised blood pressure measurement, fasting blood sampling, body composition by bioelectrical impedance, and health and lifestyle questionnaires. Results: Among screened participants, 91% presented overweight/obesity and 55% presented central adiposity, exceeding regional cardiometabolic risk thresholds (waist circumference ≥ 90 cm in men, ≥80 cm in women). Men exhibited higher waist circumference (100 ± 10.8 vs. 91.6 ± 11.9 cm), waist-to-hip ratio (0.99 ± 0.08 vs. 0.92 ± 0.07), systolic blood pressure (130 ± 12.0 vs. 122 ± 13.4 mmHg), triglycerides (168 ± 84.7 vs. 122 ± 64.9 mg/dL), VLDL-C (33.7 ± 17.2 vs. 24.4 ± 13.0 mg/dL), and sedentary time (8.1 ± 2.3 vs. 6.8 ± 2.3 h/day). Women had greater total body fat (39.7 ± 4.75% vs. 31.1 ± 5.30%), higher HDL-C (56.6 ± 13.3 vs. 46.9 ± 9.39 mg/dL), and more often had normal weight (13% vs. 0%). Conclusions: The RIO-Study provides novel insights into cardiometabolic risk and will elucidate the effects of nutritional omega-3 supplementation in a high-risk Chilean population.


  • Open Access

    Omega-3 eicosapentaenoic polar-lipid rich extract from microalgae Nannochloropsis decreases plasma triglycerides and cholesterol in a real-world normolipidemic supplement consumer population

    by Eneko Ganuza, Eghogho H. Etomi, Magdalena Olson, Corrie M. Whisner

    Introduction: AlmegaPL® is an oil rich in polar-lipid (> 15% w/w) derived from the microalga Nannochloropsis, that contains exclusively eicosapentaenoic acid (EPA > 25% w/w), without the DHA that is present in all other natural sources of omega-3. Previous findings from a randomized controlled clinical trial demonstrated the ability of AlmegaPL® supplementation to reduce cholesterol levels.Methods: In this post-market cohort study, we built upon previous findings and targeted the actual end-users of the supplement. Participants were recruited from a new subscriber database of AlmegaPL® capsules (1000–1100 mg/day) to capture the complexity of real-world clinical and consumer settings. Changes in circulating triglycerides (TG), remnant cholesterol (RC), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), total cholesterol (TC), high-sensitivity C-reactive protein (hs-CRP), glucose and glycated hemoglobin (HbA1c) were monitored at baseline, Month 3, and Month 6 of supplementation using the at-home Baseline Heart Health Testing Kit by Imaware® (Houston, TX, USA).Results: Participants, who had, on average, normal TG level at baseline (1.62 ± 0.60 mmol/L), experienced a significant and progressive decrease in TG at Month 3 (8.0%; −0.13 ± 0.59 mmol/L; p < 0.001) and Month 6 (14.2%; −0.23 ± 0.64 mmol/L; p < 0.001) (primary outcome). Furthermore, after 6 months of supplementation, TC and non-HDL-cholesterol decreased by 5.0% (−0.26 ± 0.98 mmol/L; p < 0.001) and 5.5% (−0.21 ± 0.86 mmol/L; p < 0.001) respectively, primarily driven by a 14.9% reduction in RC (−0.11 ± 0.29 mmol/L; p < 0.001).Discussion: Consistent with our previous clinical trial, the decrease in RC was not coupled to an increase in LDL, which seems to be a benefit associated with EPA-only based formulations. In addition, this study demonstrated the AlmegaPL® capacity to maintain already healthy TG levels by further inducing a 14.9% decrease. Collectively, these findings highlight AlmegaPL® uniqueness as a natural over-the-counter option for EPA-only polar lipid that appears particularly effective in maintaining blood lipid levels in a generally healthy, normolipidemic population.Clinical trial registration: https://clinicaltrials.gov/, identifier NCT05267301


  • Open Access

    A Novel Treatment Protects Chlorella at Commercial Scale from the Predatory Bacterium Vampirovibrio chlorellavorus

    by Eneko Ganuza, Charles E. Sellers, Braden W. Bennett, Eric M. Lyons, Laura T. Carney

    The predatory bacterium, Vampirovibrio chlorellavorus, can destroy a Chlorella culture in just a few days, rendering an otherwise robust algal crop into a discolored suspension of empty cells. Chlorella is used as a benchmark for open pond cultivation due to its fast growth. In nature, V. chlorellavorus plays an ecological role by controlling this widespread terrestrial and freshwater microalga, but it can have devastating effects when it attacks large commercial ponds. We discovered that V. chlorellavorus was associated with the collapse of four pilot commercial-scale (130,000 L) open-pond reactors. Routine microscopy revealed the distinctive pattern of V. chlorellavorus attachment to the algal cells, followed by algal cell clumping, culture discoloration and ultimately, growth decline. The "crash" of the algal culture coincided with increasing proportions of 16s rRNA sequencing reads assigned to V. chlorellavorus. We designed a qPCR assay to anticipate an impending culture crash and developed a novel treatment to control the bacterium. We found that 1) Chlorella growth was not affected by a 15 min exposure to pH 3.5 in the presence of 0.5 g/L acetate, when titrated with hydrochloric acid and 2) this treatment had a bactericidal effect on the culture (2-log decrease in aerobic counts). Therefore, when qPCR results indicated a rise in V. chlorellavorus amplicons, we found that the pH-shock treatment prevented the crash and doubled the productive longevity of the culture. Furthermore, the treatment could be repeatedly applied to the same culture, at the beginning of at least two sequential batch cycles. In this case, the treatment was applied preventively, further increasing the longevity of the open pond culture. In summary, the treatment reversed the infection of V. chlorellavorus as confirmed by observations of bacterial attachment to Chlorella cells and by detection of V. chlorellavorus by 16s rRNA sequencing and qPCR assay. The pH-shock treatment is highly selective against prokaryotes, and it is a cost-effective treatment that can be used throughout the scale up and production process. To our knowledge, the treatment described here is the first effective control of V. chlorellavorus and will be an important tool for the microalgal industry and biofuel research.


  • High-cell-density cultivation of Schizochytrium sp. in an ammonium/pH-auxostat fed-batch system

    by E. Ganuza, A. J. Anderson, C. Ratledge

    Thraustochytrids, in particular Schizochytrium spp., are used for the production of the valuable polyunsaturated fatty acid, docosahexaenoic acid (DHA; 22:6 n-3). Growth of Schizochytrium sp. G13/2S in a defined medium was initially made in shake-flask cultures to determine the optimum concentrations of glucose (100–200 g l−1) and ammonia (∼300 mg l−1) that could be used by this microorganism. In subsequent fermenter cultures, a pH-auxostat method was used to maintain NH3 from 200–300 mg l−1. During the first 49 h of fermentation, 150 g glucose l−1 produced 63 g cell dry wt l−1. Although growth was not limited by the supply of nitrogen, total fatty acids were at 25% cell dry wt which is more than half the final lipid content of commercially-grown Schizochytrium biomass which uses N-limited medium in the final stages for maximum lipid accumulation. This strategy is therefore useful for the cultivation of Schizochytrium to a high cell density up to the point when lipid accumulation can be triggered by N exhaustion.